activity due to
Thursday, 12:30 p.m.- # 907 - Effect of #C200
Oct. 25 2:30 p.m. small molecule
inhibitors of JAK2 Poster Session C
5:30 p.m.- kinase on modulating
7:30 p.m. signaling cascades
Thursday, 12:30 p.m.- # 985 - A small #C208
Oct. 25 2:30 p.m. molecule inhibitor of
Pim-1 kinase with Poster Session C
5:30 p.m.- activity in both
7:30 p.m. hematological and
Based in Dublin, Calif., SuperGen, Inc. is a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies. SuperGen is developing a number of therapeutic anticancer products focused on kinase and cell signaling inhibitors and DNA methyltransferase inhibitors. For more information about SuperGen, please visit http://www.supergen.com.
This news release contains certain "forward-looking" statements within
the meaning of the Private Securities Litigation Reform Act of 1995. These
statements are typically preceded by words such as "believes," "expects,"
"anticipates," "intends," "will," "may," "should," or similar expressions.
These forward-looking statements are not guarantees of future performance
and involve a number of risks and uncertainties that may cause actual
|SOURCE SuperGen Inc.|
Copyright©2007 PR Newswire.
All rights reserved